Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Sage Therapeutics (Watertown, MA) a development-stage pharmaceutical company focused on modulators of neuronal activity for schizophrenia, depression, pain and traumatic brain injury, closed a $35M Series A financing. Participants include Third Rock Ventures.

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.

Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, Greylock [...]

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

  

to top of page...